Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye disease
Biotech
AlloVir finds new identity via eye disease biotech merger
The all-stock transaction will create a combined company operating under the Kalaris brand and focused on Kalaris’ anti-VEGF drug.
James Waldron
Nov 8, 2024 9:05am
Ocuphire to transform into gene therapy biotech via Opus buyout
Oct 23, 2024 5:31am
Hibernating squirrels hold protein that clears cataracts: study
Sep 20, 2024 11:58am
Beacon attracts $170M series B to fund eye disease gene therapy
Jul 3, 2024 5:00am
Innovent's anti-VEGF drug matches Eylea in eye disease trial
Mar 19, 2024 10:36am
MeiraGTx gifts last of gene therapy rights to J&J for $415M
Dec 21, 2023 10:14am
